journal article·2025-09-17Open access

Enhanced Cancer Radiosensitization via Energy Transfer from Eu-Doped GdF3 Nanoparticles to Methylene Blue in X-ray Photodynamic Therapy

Mileni M. Isikawa, Zeinaf Muradova, Toby Morris, João V. V. Lessa, Fernanda H. Borges, Rogéria R. Gonçalves, Ross I. Berbeco, Eder J. Guidelli

ACS Applied Materials & Interfaces· Volume 17· Issue 37

Abstract

High Resolution Image Download MS PowerPoint Slide We synthesized europium-doped gadolinium fluoride (GdF 3:Eu) scintillating nanoparticles conjugated to methylene blue (MB) for singlet oxygen ( 1 O 2 ) generation in X-ray-induced photodynamic therapy (X-PDT). The impact of MB conjugation on GdF 3:Eu nanoparticles (GdF@B) was analyzed, including size, polydispersity, and surface charge. Time-resolved photoluminescence analysis demonstrated that binding of MB to the nanoparticle surface is essential for enabling efficient resonant energy transfer (ET) from the GdF 3:Eu core to the MB molecules. ET efficiencies ≥97% were obtained. 1 O 2 production exhibited energy- and dose-dependent behavior under varying radiation conditions. MTT assays demonstrated relative toxicity to LLC lung cancer mouse cells, while maintaining good tolerability in A549 human cancer cells. Clonogenic assays showed significant cytotoxicity in A549 cells only after X-ray exposure, confirming a reduced clonogenic survival. Survival fraction curves were analyzed using the linear-quadratic model, the sensitization enhancement factor, and the dose enhancement factor, highlighting the contributions of both the high atomic number of GdF 3:Eu cores and 1 O 2 generation. The findings indicate that GdF@B enables deep-tissue ROS generation, overcoming light penetration limitations in traditional PDT. Additionally, these nanoparticles show potential to enhance radiotherapy efficacy in both conventional fractionated protocols and advanced radiosurgery techniques, offering a promising cancer treatment nanoplatform.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence Properties of Advanced Materials · Radiation Therapy and Dosimetry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Departamento de Física - FFCLRP

Universidade de São Paulo

Department of Radiation Oncology, Brigham and Women’s Hospital

Dana-Farber Cancer Institute, Harvard Medical School

Department of Physics and Applied Physics

University of Massachusetts Lowell

Departamento de Química, Center for Nanotechnology and Tissue Engineering & Mater Lumen Laboratory − FFCLRP

Funding

Fulbright U.S. Scholar Program · Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico · Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo · American Association of Physicists in Medicine · Banco Santander · Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior

References (55)

Show source-provided references
1. 10.3390/ijms2111400410.3390/ijms21114004 ↗
2. 10.2217/NNM.13.19810.2217/NNM.13.198 ↗
3. 10.1021/ACSNANO.2C0804710.1021/ACSNANO.2C08047 ↗
4. 10.1002/adhm.20240037210.1002/adhm.202400372 ↗
5. 10.1016/j.ccr.2022.21497910.1016/j.ccr.2022.214979 ↗
6. 10.4103/0970-9290.6665910.4103/0970-9290.66659 ↗
7. 10.1155/2022/721148510.1155/2022/7211485 ↗
8. 10.1111/php.1358110.1111/php.13581 ↗
9. 10.3390/nano1304067310.3390/nano13040673 ↗
10. 10.1111/php.1355010.1111/php.13550 ↗
11. 10.1039/c8pp00112j10.1039/c8pp00112j ↗
12. 10.1039/d3ra04984a10.1039/d3ra04984a ↗
13. 10.1002/ADMA.20180802410.1002/ADMA.201808024 ↗
14. 10.1021/acsami.0c1904110.1021/acsami.0c19041 ↗
15. 10.1016/j.ijrobp.2008.06.191610.1016/j.ijrobp.2008.06.1916 ↗
16. 10.1007/S12030-008-9009-X10.1007/S12030-008-9009-X ↗
17. 10.1021/acs.chemmater.8b0358710.1021/acs.chemmater.8b03587 ↗
18. 10.1038/s41467-022-30982-510.1038/s41467-022-30982-5 ↗
19. 10.1016/j.radmeas.2018.12.00810.1016/j.radmeas.2018.12.008 ↗
20. 10.1039/D4NA00640B10.1039/D4NA00640B ↗
21. 10.7150/thno.1614110.7150/thno.16141 ↗
22. 10.1039/C8CS00921J10.1039/C8CS00921J ↗
23. 10.1039/b510982p10.1039/b510982p ↗
24. 10.1021/ACSAMI.1C2068910.1021/ACSAMI.1C20689 ↗
25. Lakowicz J. R. · 200610.1007/978-0-387-46312-4 ↗
26. 10.1007/978-1-60327-198-1_610.1007/978-1-60327-198-1_6 ↗
27. 10.1016/j.jallcom.2010.10.14310.1016/j.jallcom.2010.10.143 ↗
28. 10.1016/j.carbon.2020.02.06410.1016/j.carbon.2020.02.064 ↗
29. 10.1016/j.ccr.2015.02.01510.1016/j.ccr.2015.02.015 ↗
30. 10.3389/fphar.2023.126496110.3389/fphar.2023.1264961 ↗
31. 10.1016/j.jlumin.2017.08.04410.1016/j.jlumin.2017.08.044 ↗
32. 10.1016/j.molliq.2014.06.03010.1016/j.molliq.2014.06.030 ↗
33. 10.1021/acs.jpcb.5b1184710.1021/acs.jpcb.5b11847 ↗
34. 10.3164/jcbn.10-12510.3164/jcbn.10-125 ↗
35. 10.11425/sst.7.6110.11425/sst.7.61 ↗
36. 10.3390/toxics1010062810.3390/toxics10100628 ↗
37. 10.1016/j.msec.2021.11212210.1016/j.msec.2021.112122 ↗
38. 10.1246/cl.13061810.1246/cl.130618 ↗
39. 10.1021/ACSAMI.3C0085310.1021/ACSAMI.3C00853 ↗
40. 10.1039/C4NR07444K10.1039/C4NR07444K ↗
41. 10.1126/sageke.2003.30.pe2110.1126/sageke.2003.30.pe21 ↗
42. 10.1038/ncb102410.1038/ncb1024 ↗
43. 10.1042/BJ2008138610.1042/BJ20081386 ↗
44. 10.1016/S0891-5849(02)00910-310.1016/S0891-5849(02)00910-3 ↗
45. 10.1038/nrc123510.1038/nrc1235 ↗
46. 10.2147/ijn.s35930010.2147/ijn.s359300 ↗
47. 10.1155/2013/94291610.1155/2013/942916 ↗
48. 10.1021/acs.jpcc.8b0938110.1021/acs.jpcc.8b09381 ↗
49. 10.1246/cl.2006.83210.1246/cl.2006.832 ↗
50. 10.1080/17435390.2017.127935910.1080/17435390.2017.1279359 ↗
51. P-Value: What It Is, How to Calculate It, and Why It Matters. https://www.investopedia.com/terms/p/p-value.asp (accessed Apr 13, 2023).
52. 10.1186/s13014-016-0584-z10.1186/s13014-016-0584-z ↗
53. 10.1186/S13014-020-01697-Y10.1186/S13014-020-01697-Y ↗
54. Hall E. J. · 2012
55. 10.7150/thno.2735110.7150/thno.27351 ↗